Hinge Health Beats With 52% Revenue Growth, Raises Full-Year Guidance
HNGE has more than doubled off its 52-week low of $30.08.
Summary
Hinge Health delivered a blowout Q3 2026: revenue rose 52% year-over-year to $235.0 million, and GAAP operating income swung to $50.3 million from a $6.1 million loss a year ago. Non-GAAP operating income jumped 154% to $77.2 million, a 33% margin versus 20% last year, and non-GAAP diluted EPS came in at $0.71 versus $0.32. The company raised full-year 2026 revenue guidance to $879-881 million (50% growth at the midpoint) and lifted non-GAAP operating income guidance to $266-268 million, up 123% year-over-year. LTM calculated billings of $960.3 million, up 54%, and 3,270 clients, up 28%, show the sales engine is still accelerating, with management calling it a record sales season and citing client growth of roughly 40% for the GI program since the Cylinder Health acquisition announced in August. On the leadership front, President Jim Pursley steps down January 1, 2027, moving to the board, with Aaryn Pure taking over as Chief Commercial Officer; co-founder and CEO Daniel Perez will also serve as President effective January 1, 2027, and Pursley joins the board January 4, 2027 with a $40,000 annual retainer and a 40,000-RSU advisory grant. The stock sits near its 52-week high of $118.87, so the raised guidance and margin expansion are the numbers that matter into the Q4 print.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Daniel Perez, co-founder and CEO, will also serve as President effective January 1, 2027; Pursley joins the board January 4, 2027 with a $40,000 annual retainer and a 40,000-RSU advisory grant.
At the time of this announcement, HNGE was trading at $113.80 on NYSE in the Life Sciences sector, with a market capitalization of approximately $9.3B. The 52-week trading range was $30.08 to $118.87. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.